Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups.
Epistemonikos ID: f79fba5ecf827ca09cf946ed560394b2598e30ef
First added on: May 04, 2024